Stocks and Investing Stocks and Investing
Wed, April 13, 2016
Tue, April 12, 2016
Mon, April 11, 2016
Fri, April 8, 2016
Thu, April 7, 2016
Wed, April 6, 2016
Tue, April 5, 2016
Mon, April 4, 2016
Fri, April 1, 2016
Thu, March 31, 2016
Wed, March 30, 2016
Tue, March 29, 2016
Mon, March 28, 2016
Thu, March 24, 2016
Wed, March 23, 2016
Tue, March 22, 2016

Kennen MacKay Maintained (BMRN) at Buy with Decreased Target to $109 on, Mar 22nd, 2016


Published on 2024-10-25 12:00:16 - WOPRAI, Kennen MacKay
  Print publication without navigation


Kennen MacKay of Credit Suisse, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Decreased Target from $114 to $109 on, Mar 22nd, 2016.

Kennen has made no other calls on BMRN in the last 4 months.



There are 2 other peers that have a rating on BMRN. Out of the 2 peers that are also analyzing BMRN, 0 agree with Kennen's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Kennen


  • Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $105 on, Friday, February 26th, 2016
  • Joseph Schwartz of "Leerink Swann" Maintained at Buy with Decreased Target to $120 on, Tuesday, February 23rd, 2016